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Abstract: An increasing number of evidence suggests that clinical variables alone are not enough to predict the 
survival of patients with muscle invasive bladder cancer (MIBC), and the expression of mRNAs, long non-coding 
RNAs (lncRNAs) and microRNAs (miRNAs) also plays an important role in the onset of MIBC. This study aims to 
establish a more accurate model for predicting the overall survival of MIBC based on clinical information and 
genetic characteristics. In this study, the RNAs profiles and clinical variable data of patients with MIBC were 
downloaded from the Cancer Genome Atlas (TCGA) database. Univariate Cox regression analysis, differential 
expression analysis and elastic net-regulated Cox regression analysis were used to identify the clinical variables and 
RNAs (mRNAs, lncRNAs and miRNAs) related to the prognosis of MIBC. Prognostic models of MIBC were 
established by multivariate Cox regression and ridge regression analysis using the identified prognostic clinical 
variables and RNAs. Three clinical variables, 25 mRNAs, 3 lncRNAs and 2 miRNAs related to the prognosis of 
MIBC were identified, and an integrated signature, a clinical variable signature, and an mRNA-lncRNA-miRNA 
signature were established based on the identified clinical variables and/or RNAs. Among the three models, the 
integrated signature had the highest predictive accuracy (5-year the area under the curve (AUC)=0.835, 95%CI: 
0.776-0.894) among the three models (P < 0.05). The patients in the TCGA MIBC cohort were classified into high- 
or low-risk groups by the integrated signature, and it was found that the patients in the low-risk group had a 
significantly longer overall survival time compared with the patients in the high-risk group (P < 0.001). Applying 
published gene signatures and TCGA data, a new and more accurate integrated clinical-mRNA-lncRNA-miRNA 
signature for MIBC prognostic was established. 
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1. Introduction 
Bladder cancer (BC), a kind of malignant tumor that develops on the bladder mucosa, ranks first 
among urogenital system tumors in China and next only to prostate cancer in western countries [1, 2]. 
Previous studies show that 15%-30% of BC are muscle invasive bladder cancer (MIBC) with high 
degree of malignancy, and are usually treated with radical cystectomy plus pelvic lymph node 
dissection and systemic chemotherapy thereafter [3]. However, the postoperative 5-year survival rate 
was only 66% [4]. Due to high recurrence and metastasis rate of MIBC, it is important to carry out 
studies onthe improvement of prognosis. Currently, the prognosis of patients with MIBC is predicted 
mainly based on tumor size, multiple lesions, age and other clinical variables [5-7]. Recently, several 
studies showed that biological alterations in specific genes or molecules could affect the prognosis of 
MIBC patients [8-10]. Thus, it is necessary to investigate the prognosis-related clinical variables and 
biomarkers of MIBC, to obtain a prognostic model with high prediction accuracy and assist in the 
development of rational individualized treatment regimen. 
 With the development of high throughput sequencing technique, gene expression of mRNAs 
and non-coding RNAs (ncRNA) were widely used in the prognosis of patients with MIBC [8, 9, 11]. 
Liu et al. [12] established a prognostic model integrated with TNM stage and six selected 
PCG-lncRNA-miRNA signature of patients with BC, which was superior to the prognostic model of 
TNM stage signature and the prognostic model of PCG-lncRNA-miRNA signature in predictive ability, 
but only one clinical variable (TNM stage) was presented in this model. Xiong et al. [7] also found 
that a prognostic model integrated with clinical-mRNA-miRNA signature was superior to the 
clinical-alone signature in predicting the overall survival (OS) of BC, but lncRNAs signature was 
missing in this model. According to our knowledge, there was no integrated prognostic model of 
clinical variables and mRNAs, lncRNAs and miRNAs signature for MIBC. Thus, we obtained the 
clinical variable data and mRNAs, miRNAs and lncRNAs expression profiles of patients with MIBC 
from The Cancer Genome Atlas (TCGA) database. We aimed to construct a more accurate prognosis 
model and provide new genomics clues for the formation and metastasis study of BC. 
2. Materials and methods 
2.1 Patient information and RNA profiles    
Demographic information (genders, races, smoking history), clinical data (diagnostic age, clinical 
stage of tumor, neoplasm histologic grade, TNM staging, diagnostic subtypes and OS and RNA 
profiles of cancer tissue and paracancerous tissue of MIBC patients (mRNAs, lncRNAs andmiRNAs 
profiles at Level 3) were downloaded from the TCGA database (https://portal.gdc.cancer.gov/). The 
exclusion criteria were survival time less than 30 days after initial pathologic diagnosis. The qualified 
MIBC patients were included in the TCGA MIBC cohort for this study. Survival time of patients was 
defined as a time span between the initial diagnosis and all-cause death. 
2.2 Data preprocessing 
The data obtained from the TCGA database were pre-processed as follows: (1) for each of the clinical 
variables, when the data missing rate was less than 10%, the missing data was filled by the 
Classification and Regression Trees method; (2) the RNA sequence data was generated by Illumina 
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HiSeq RNA-Seq platform, and the RNA sequence was annotated (annotation file: GENCODE.V29) to 
obtain mRNA and lncRNA profiles, then the mRNA and lncRNA profiles was standardized by the 
Transcripts Per Million Reads method; and the miRNA sequence data was generated by Illumina 
HiSeq miRNA-Seq platform; (3) the expression of each RNA gene in patients was divided into low 
expression and high expression by using the median of expression of each RNA gene as the cut-off 
point for univariate Cox regression analysis. 
2.3 Identification of prognostic variables  
The clinical variables were filtered out by univariate Cox regression at first, then the clinical variables 
with P value ≤ 0.05 were enrolled in a multivariate Cox regression. Finally, the clinical variables with 
P value ≤ 0.05 in multivariate Cox regression were identified as the significant factors of the prognosis 
of MIBC. 
 mRNA, lncRNA and miRNA related to the prognosis of MIBC were identified by the 
following three steps: (1) the RNAs with |log2FC| > 2 (Fold Change, FC) and false discovery rate 
(FDR) < 0.01 were preliminarily screened as the differentially expressed genes. (2) for the 
differentially expressed genes, the RNAs with a univariate Cox regression P value < 0.01 were taken 
as the significant genes of the MIBC prognosis. (3) we fitted an elastic net-regulated Cox regression 
with 10,000 iterations and 10 cross-validations using the significant genes of the MIBC prognosis with 
a univariate Cox regression P value < 0.01. RNAs with elastic net-regulated Cox regression 
coefficient≠0 were taken as the identified candidate genes related to the prognosis of MIBC. 
2.4 Prognosis index and model development 
For each patient of MIBC, a prognosis index (PI) was calculated as an integrated indicator of the 
identified candidate clinical variables and (or) RNAs. Weighted prognostic index (WPI) was defined 
as the standard form of the PI. Specifically, 
 
𝑃𝑃𝑃𝑃 = �(𝛽𝛽𝑖𝑖 × 𝑉𝑉𝑖𝑖)
𝑖𝑖
 
𝑊𝑊𝑃𝑃𝑃𝑃 = 𝑃𝑃𝑃𝑃 − 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀(𝑃𝑃𝑃𝑃)
𝑆𝑆𝑆𝑆(𝑃𝑃𝑃𝑃)  
where, PI is the prognostic index of the each observation. βi is the regression coefficient of the ith 
variable. Mean (PI) and SD (PI) are the mean and standard deviation of the PI vector, respectively. For 
the clinical variable signature, Vi is the observed value of the ith clinical variable, and βi is the 
multivariate Cox regression coefficient of the ith clinical variable. For the RNA signature, Vi is the 
expression value of each RNA, and βi is the ridge regression coefficient of the ith RNA. For the 
integrated clinical-RNA signature, Vi is the expression value of each RNA or observed value of 
clinical variable, and βi is the ridge regression coefficient of the ith RNA or clinical variable. 
2.5 Model evaluation 
The area under the curve (AUC) of the time-dependent receiver operating characteristic (ROC) of the 
three prognostic models were separately calculated. The efficiency of the three models to predict the 
prognosis of MIBC was evaluated by comparing the AUC values. The model with the maximum AUC 
value was defined as the best prognosis model, and its PI and WPI were used as 𝑃𝑃𝑃𝑃best  and 𝑊𝑊𝑃𝑃𝑃𝑃best . 
The mean of the 𝑊𝑊𝑃𝑃𝑃𝑃best  was taken as the cut-off point (𝑊𝑊𝑃𝑃𝑃𝑃cut ) if the distribution characteristics of 
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the 𝑊𝑊𝑃𝑃𝑃𝑃best  values was symmetrical, or the median of the 𝑊𝑊𝑃𝑃𝑃𝑃best  was taken as the 𝑊𝑊𝑃𝑃𝑃𝑃cut  if the 
distribution characteristics of the 𝑊𝑊𝑃𝑃𝑃𝑃best  values was skewed. According to the 𝑊𝑊𝑃𝑃𝑃𝑃cut , the MIBC 
patients were divided into two subgroups: a low-risk group (𝑊𝑊𝑃𝑃𝑃𝑃best  ≤  𝑊𝑊𝑃𝑃𝑃𝑃cut ) and a high-risk group 
(𝑊𝑊𝑃𝑃𝑃𝑃best  >  𝑊𝑊𝑃𝑃𝑃𝑃cut ). We compared the OS time of the 2 groups using the Kaplan-Meier survival 
curves and log-rank test.  
All the above analyses were performed using RStudio 1.1.463. 
2.6 Gene function enrichment analysis 
Gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
enrichment were carried out based on validated genes using WebGestalt 2019 [13] 
(http://www.WebGestalt.org). The validated genes for GO and KEGG enrichment included as follows: 
(1) the identified candidate mRNAs in this study; (2) the target mRNAs of the identified candidate 
miRNAs in this study obtained from miRDB database; (3) the mRNAs obtained from TCGA database 
in this study were correlated with the identified candidate lncRNAs. 
3. Results 
3.1 Patient information and RNA profiles  
A total of 409 patients with MIBC were reviewed, and 19 of them were excluded due to the following 
reasons: missing survival time (n=2), incomplete mRNA, lncRNA and miRNA profiles (n=7), and 
death within 30 days of the initial pathologic diagnosis (n=10). Finally, 390 patients were included in 
the TCGA MIBC cohort for further study. Of this cohort, 19 patients had RNAs profiles of 
paracancerous tissues. 
 The demographic and clinical characteristics of these patients were shown in Table 1. The 
RNA profiles of this cohort included 19,364 mRNA, 5,217 lncRNA and 1,882 miRNA profiles. 
 
Table 1 Survival analysis results of demographic variables and clinical variables. 
Variables Patients  
n(%) 
Univariate Cox  Multivariate Cox  
HR(95%CI) P value HR(95%CI) P value 
Diagnostic Age 390(67.83)* 1.03(1.02-1.05) < 0.001 1.03(1.02-1.05) < 0.001 
Clinical Stage 1.71(1.40-2.08) < 0.001 1.47(1.20-1.79) < 0.001 
Ⅰ 0（0.00）     
Ⅱ 123(31.54)     
Ⅲ 136(34.87)     
Ⅳ 129(33.08)     
Missed 2(0.51)     
TNM-N stage 1.24(1.12-1.37) < 0.001 1.21(1.07-1.36) 0.003 
N0 226(57.95)     
N1 43(11.03)     
N2 75(19.23)     
N3 7(1.79)     
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NX 35(8.97)     
Missed 4(1.03)     
TNM-T stage 1.22(1.01-1.47) 0.042   
T1 8(2.05)     
T2 185(47.44)     
T3 150(38.46)     
T4 41(10.51)     
TX 6(1.54)     
TNM-M stage 1.20(1.03-1.40) 0.018   
M0 186(47.69)     
M1 10(2.57)     
MX 192(49.23)     
Missed 2(0.51)     
Diagnostic Subtype  1.55(1.08-2.21) 0.017   
Papillary 124(31.80)     
Non-papillary 261(66.92)     
Missed 5(1.28)     
Gender  1.20(0.86-1.66) 0.277   
Female 103(26.41)     
Male 287(73.59)     
Human Racea      
White 312(80.00) 1.05(0.67-1.65) 0.818   
Asian 39(10.00) 0.65(0.33-1.28) 0.215   
Black# 22(5.64) 1.37(0.78-2.42) 0.271   
Missed 17(4.36)     
Neoplasm Histologic Grade 2.76(0.68-11.16) 0.154   
Low 18(4.62)     
High 369(94.62)     
Missed 3(0.76)     
Smoking History 1.35(0.94-1.92) 0.101   
Non-smoking 105(26.93)     
Smoking 272(69.74)     
Missed 13(3.33)     
a: dumb variable. *: n (mean, year). #: black or African American. 
3.2 Prognostic clinical variables for MIBC 
The following clinical variables were significantly associated with the prognosis of MIBC: diagnostic 
age (HR=1.03, 95%CI: 1.02-1.05), clinical stage (HR=1.47, 95%CI: 1.20-1.79) and TNM-N stage 
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(HR=1.21, 95%CI: 1.07-1.36). With the increase of age, clinical stage and TNM-N stage in MIBC 
patients, there was increased risk of all-cause mortality (Table 1). 
3.3 Prognostic RNAs for MIBC 
A total of 3,908 differentially expressed genes between cancer and the paracancer screened including 
3,781 (1,994, up-regulated; 1,787, down-regulated) differentially expressed mRNAs, 53 differentially 
expressed lncRNAs (21, up-regulated; 32, down-regulated) and 74 differentially expressed miRNAs 
(16, up-regulated; 58, down-regulated) were obtained. The results of the univariate Cox regression 
showed that there were 107 RNAs (78 mRNAs, 14 lncRNAs and 15 miRNAs) were identified as 
potential predictors of OS in patients with MIBC (P < 0.01). For further, the 107 RNAs were screened 
by fitting elastic net-regulated Cox regression. The results revealed that the regression coefficient of 
30 selected candidate RNAs (25 mRNAs, 3 lncRNAs and 2 miRNAs) was over 0, suggesting that 
these 30 candidate RNAs were related to the prognosis of MIBC (Table 2). 
 
Table 2 Thirty candidate RNAs for the integrated signature. 
 
Number Gene symbol HR‖ 95%CI P value* Regulation# Coefficient§ 
mRNA       
1 LSM7 0.45 0.32-0.64 < 0.001 Down -0.0817 
2 TMEM259 0.47 0.33-0.65 < 0.001 Down -0.1928 
3 PRRG2 0.47 0.33-0.67 < 0.001 Down -0.1609 
4 CCDC61 0.47 0.33-0.67 < 0.001 Down -0.1080 
5 OCIAD2 0.47 0.33-0.68 < 0.001 Down -0.0132 
6 GEMIN7 0.49 0.34-0.70 < 0.001 Down -0.0336 
7 SPINT2 0.50 0.35-0.74 < 0.001 Down -0.0613 
8 ZNF600 0.51 0.35-0.73 < 0.001 Down -0.0553 
9 C19orf25 0.52 0.37-0.72 < 0.001 Down -0.2209 
10 KLHDC4 0.54 0.38-0.76 < 0.001 Down -0.0579 
11 TMC6 0.54 0.37-0.78 0.001 Down -0.0125 
12 RBPMS 0.57 0.40-0.80 0.001 Up -0.0649 
13 PID1 1.77 1.30-2.40 < 0.001 Up 0.0556 
14 DIXDC1 1.80 1.30-2.49 < 0.001 Up 0.0015 
15 OGN 1.81 1.34-2.45 < 0.001 Up 0.0057 
16 NHSL2 1.81 1.32-2.49 < 0.001 Up 0.0843 
17 SERPINB12 1.81 1.31-2.49 < 0.001 Up 0.2234 
18 SETBP1 1.83 1.35-2.49 < 0.001 Up 0.0908 
19 TMOD1 1.83 1.35-2.49 < 0.001 Up 0.1079 
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20 CASQ2 1.88 1.39-2.54 < 0.001 Up 0.0391 
21 PTGIS 1.91 1.35-2.70 < 0.001 Up 0.0568 
22 ITGA7 1.91 1.29-2.82 0.001 Up 0.1859 
23 SCN4B 1.95 1.44-2.64 < 0.001 Up 0.3103 
24 MAP1B 2.08 1.42-3.04 < 0.001 Up 0.1689 
25 EPHB1 2.15 1.55-2.98 < 0.001 Up 0.1686 
lncRNA       
26 AC097534.2 0.71 0.53-0.96 0.002 Up -0.3506 
27 AC021016.2 0.72 0.53-0.99 0.004 Up -0.1956 
28 LINC01184 1.78 1.10-2.87 0.001 Up 0.5666 
miRNA       
29 hsa-mir-651 0.62 0.46-0.85 0.003 Down -0.0220 
30 hsa-mir-1976 0.50 0.34-0.72 < 0.001 Down -0.0139 
Abbreviations: HR, hazard ratio; CI, confidence interval. 
*Univariate Cox regression P value < 0.01 was considered statistically significant.  
# type of regulation (upregulated or downregulated) in Bladder cancer patients vs normal controls. 
§Elastic net-regulated Cox regression coefficient. 
‖Protective RNAs had a hazard ratio < 1 and risky RNAs had a hazard ratio > 1 in bladder cancer patients 
as determined by univariate Cox regression. 
 
Table 3 AUC values of the three kind of prognostic models. 
Prognostic Model 
1-yeara  3-yearb  5-yearc 
 AUC 95%CI   AUC 95%CI  AUC 95%CI 
1. clinical variable signature 0.713 0.651-0.776  0.699 0.631-0.769  0.707 0.622-0.793 
2. mRNA-lncRNA-miRNA 
signature 
0.706 0.639-0.774  0.793 0.734-0.852  0.793 0.725-0.861 
3. integrated signature 0.763 0.702-0.823  0.827 0.772-0.882  0.835 0.776-0.894 
a: The AUC values of Model 1 and Model 2 were compared with that of Model 3, and P values were 0.145 and < 0.001, 
respectively.  
b: The AUC values of Model 1 and Model 2 were compared with that of Model 3, and P values were < 0.001 and 0.021, 
respectively. 
c: The AUC values of Model 1 and Model 2 were compared with that of Model 3, and P values were < 0.001 and 0.024, 
respectively. 
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3.4 Prognostic model for MIBC 
Clinical variable signature (Model 1): the value of the PI for Model 1 was calculated by the following 
formula: PI=0.033*X1+0.382*X2+0.187*X3, and X1, X2 and X3 in the formula were the identified 
clinical variables, which were diagnostic age, clinical stage and TNM-N stage, respectively (Table 1). 
As to Model 1, the AUC values of ROC at 1-year, 3-year and 5-year were 0.713 (95%CI: 0.651-0.776), 
0.699 (95%CI: 0.631-0.769) and 0.707 (95%CI: 0.622-0.793), respectively. This result indicated that 
Model 1 can accurately predict the prognosis of MIBC (Table 3, Fig. 1). 
 
 
Fig. 1 ROC curves for the clinical variable signature (Model 1), mRNA-lncRNA-miRNA signature (Model 2) and 
integrated signature (Model 3). A: 1-year ROC curve; B: 3-year ROC curve; C: 5-year ROC curve. 
Table 4 mRNA-lncRNA-miRNA signature ridge regression model. 
No. Gene symbol Coefficient No. Gene symbol Coefficient 
1 LSM7 -0.11236 16 NHSL2 0.10920 
2 TMEM259 -0.14759 17 SERPINB12 0.18034 
3 PRRG2 -0.14256 18 SETBP1 0.12176 
4 CCDC61 -0.08467 19 TMOD1  0.10711 
5 OCIAD2 -0.06095 20 CASQ2 0.05853 
6 GEMIN7 -0.08146 21 PTGIS 0.10672 
7 SPINT2 -0.11538 22 ITGA7 0.20852 
8 ZNF600 -0.07962 23 SCN4B 0.25273 
9 C19orf25 -0.19050 24 MAP1B 0.16588 
10 KLHDC4 -0.07556 25 EPHB1 0.15126 
11 TMC6 -0.11435 26 AC097534.2* -0.34230 
12 RBPMS -0.13521 27 AC021016.2* -0.24680 
13 PID1 0.09729 28 LINC01184* 0.53358 
14 DIXDC1 0.06041 29 has-mir-651# -0.06155 
15 OGN 0.04545 30 hsa-mir-1976# -0.07795 
*: lncRNA. #: miRNA 
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 mRNA-lncRNA-miRNA signature (Model 2): Model 2 was established based on the 
identified 30 RNAs in this study (Table 4). Regarding Model 2, the AUC values of ROC at 1-year, 
3-year and 5-year were 0.706 (95%CI: 0.639-0.774), 0.793 (95%CI: 0.734-0.852) and 0.793 (95%CI: 
0.725-0.861), respectively. This result suggested that this RNAs signature (Model 2) can accurately 
predict the prognosis of MIBC (Table 3, Fig. 1). 
 Integrated signature (Model 3): Model 3 was established based on the identified 3 clinical 
variables and 30 RNAs in this study (Table 5). For Model 3, the AUC values of ROC at 1-year, 3-year 
and 5-year were greater than those of the other two models, and the minimum AUC value of ROC was 
0.763 (95%CI: 0.702-0.823), which was the AUC value at 1-year. 
 
Table 5 Integrated signature ridge regression model. 
No. Symbol Coefficient No. Symbol Coefficient 
1 LSM7 -0.09845 18 SETBP1 0.16407 
2 TMEM259 -0.13468 19 TMOD1 0.07921 
3 PRRG2 -0.19806 20 CASQ2 0.04033 
4 CCDC61 -0.07815 21 PTGIS 0.08012 
5 OCIAD2 -0.09788 22 ITGA7 0.12968 
6 GEMIN7 -0.08696 23 SCN4B 0.24782 
7 SPINT2 -0.15221 24 MAP1B 0.15625 
8 ZNF600 -0.05400 25 EPHB1 0.13183 
9 C19orf25 -0.13733 26 AC097534.2* -0.31203 
10 KLHDC4 0.00340 27 AC021016.2* -0.19513 
11 TMC6 -0.10502 28 LINC01184* 0.50612 
12 RBPMS -0.13213 29 has-mir-651# 0.00075 
13 PID1 0.11719 30 hsa-mir-1976# -0.05994 
14 DIXDC1 0.09981 31 Clinical stage 0.16541 
15 OGN -0.00609 32 Diagnostic age 0.01550 
16 NHSL2 0.13559 33 TNM -N stage 0.15239 
17 SERPINB12 0.23608    
*: lncRNA, #: miRNA. 
 Among the three models, the maximum AUC value of ROC was 0.835 (95%CI: 0.776-0.894), 
which was the AUC value of Model 3 at 5-year. These results suggested that the Model 3 was superior 
to the Model 1 or the Model 2, then Model 3 was defined as the best prognosis model for MIBC (Table 
3, Fig. 1). 
3.5 Evaluation for the best prognostic model 
The PI and WPI of the integrated signature (Model 3) were taken as the 𝑃𝑃𝑃𝑃best  and 𝑊𝑊𝑃𝑃𝑃𝑃best  of the 
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best model. The distribution of the 𝑊𝑊𝑃𝑃𝑃𝑃best  values of the TCGA MIBC cohort (n=390) was positive 
skewness, therefore, the median of the 𝑊𝑊𝑃𝑃𝑃𝑃best  with a value of -0.046 was used as the 𝑊𝑊𝑃𝑃𝑃𝑃cut  for the 
cohort classification. The patients of the cohort were divided into two subgroups, 195 patients 
with 𝑊𝑊𝑃𝑃𝑃𝑃best  value less than or equal to 𝑊𝑊𝑃𝑃𝑃𝑃cut  were classified into low-risk group, and the other 
195 patients were classified into low-risk group. The results of the Kaplan-Meier survival curves and 
the log-rank test (P < 0.001) showed that the patients in the low-risk group had better prognosis than 
high-risk group patients (Fig. 2). 
 
 
Fig.2 Kaplan-Meier Survival curves for the low-risk group and the high-risk group segregated by the 
clinical-mRNA-lncRNA-miRNA signature (Model 3) in the TCGA MIBC cohort. 
 
 
Fig.3 GO analysis of the 424 validated genes 
 
3.6 GO and KEGG enrichment analyses 
GO and KEGG pathway enrichment analyses were conducted for the 424 validated genes which were 
associated with the prognosis of MIBC in this study. The functions of these 424 genes were mainly 
enriched in the process of biological regulation and metabolism. For cell composition analysis, the 
products of the 424 genes were located in the nucleus and cell membrane. In addition, most of the 424 
genes were related to ion binding, nucleic acid binding and transferase activity (Fig. 3). The function 
of these 424 genes was enriched in tumor transcriptional disorders, MAPK signaling pathway and 
AMPK signaling pathway (Fig. 4).  
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Fig.4 KEGG analysis of the 424 validated genes 
4. Discussion 
Based on the data of TCGA database, we analyzed the relevance between the clinical variables and 
mRNA, lncRNA and miRNA expression and the prognosis of patients with MIBC. The identified 
clinical variables and mRNAs, lncRNAs and miRNAs related to the prognosis of MIBC were used to 
establish the prognostic model. As the first established prognostic model integrating clinical variables 
and mRNAs, lncRNAs and miRNAs signature, the integrated signature had the highest predictive 
accuracy (5-year AUC=0.835, 95%CI: 0.776-0.894) among the three models (P < 0.05). The 
integrated signature was used to classify the prognosis of MIBC patients, the survival rate of patients 
in the low-risk subgroup was higher than that in the high-risk subgroup (P < 0.001), suggesting the 
good predictive effect of this model. 
 The integrated signature established in this study included 3 clinical variables and 25 
mRNAs, 3 lncRNAs and 2 miRNAs signature related to the prognosis of MIBC. In accordance with 
previous studies, we also found diagnostic age, clinical stage and TNM-N stage were independent 
prognostic variables in MIBC patients [5, 6]. Recently, several studies showed that the expression of 
lncRNAs affected the prognosis of BC [11, 14]. Therefore, our integrated signature added lncRNA 
signature. The introduction of lncRNA signature improved the predictive ability of the model. 
Compared with the literature [12], our integrated signature increased the effect of diagnostic age and 
clinical stage and improved the predictive accuracy of prognosis.  
 In this study, we identified 25 mRNAs related to the prognosis of MIBC, including 12 
protective mRNAs (HR < 1) (LSM7, TMEM259, PRRG2, CCDC61, OCIAD2, GEMIN7, SPINT2, 
ZNF600, C19orf25, KLHDC4, TMC6, RBPMS) and 13 risk mRNAs (HR > 1) (PID1, DIXDC1, OGN, 
NHSL2, SERPINB12, SETBP1, TMOD1, CASQ2, PTGIS, ITGA7, SCN4B, MAP1B, EPHB1). Of the 
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prognostic mRNAs, DIXDC1 was previously reported to a novel component of the Wnt pathway, 
which played key roles in development, cell growth, differentiation, polarity formation, neural 
development, and carcinogenesis [15]. Moreover, it has been reported that inhibition of DIXDC1 by 
microRNA-582-5p and -3p suppresses the proliferation and invasion of BC [16]. Furthermore, PTGIS 
is a major regulator in hypoxic cancer progression by activating transcription of various oncogenes 
[17]. In the competitive endogenous RNA net analysis of BC, MAP1B interacted as a node with 
lncRNA and miRNA to regulate transcription [18]. The interaction between MAP1B and p53 affected 
the apoptosis and proliferation of cells [19]. Alpha-7 integrin is a protein that is encoded by the ITGA7，
and appears to be a tumor suppressor that operates by suppressing tumor growth and retarding 
migration [20]. ITGA7 were forecast to play important roles in the occurrence and progression of BC 
[21]. LncRNAs had longer sequences and more complex spatial structures than other types of RNAs 
and participated in cell proliferation, transformation and other functional activities, and the change of 
lncRNA expression level had an important impact on the occurrence and development of many kinds 
of tumors [22-24]. Of the three lncRNAs identified in this study, 2 were protective lncRNAs 
(AC097534.2 and AC021016.2) (HR < 1) and 1 was risk lncRNA (LINC01184) (HR > 1). With 
oncogenes or anti-oncogenes, miRNAs could affect the proliferation and differentiation of cancer cells 
[25-27]. The expression of 2 miRNAs (hsa-mir-651 and hsa-mir-1976) identified in this study was 
down-regulated in patients with MIBC, and the high expression of these 2 miRNAs gene could reduce 
the prognostic death risk of patients with MIBC (HR < 1), both of which were protective miRNAs 
(anti-oncogenes). The role and mechanism of the 3 lncRNAs and 2 miRNAs in the occurrence and 
development of MIBC need to be verified by further experimental study. The results of GO and KEGG 
analysis of the 424 genes related to the prognosis of MIBC in this study showed that the functions of 
these genes mainly affected the nucleic acid binding and transferase activity, and was enriched in 
MAPK and AMPK signaling pathway of tumor. Considering that MAPK signaling pathway played a 
key role in tumor formation and metastasis [28], it was suggested that RNAs identified in this study 
might play an important role in the occurrence and development of MIBC. 
 This study has several potential limitations. First, the predictive accuracy of the prognostic 
model of integrated signature was needed for further evaluation using other BC data. Second, the 
function of the identified RNAs needs to be confirmed by experiments. 
 In summary, a prognostic model of integrated signature for MIBC established in our study 
has a better predictive effect of prognosis than that of clinical variable signature and 
mRNA-lncRNA-miRNA signature. The results of our study can provide new genomics clues for the 
formation and metastasis of MIBC. 
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